You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of Novel Small Molecule Anti-Fibrotic Agent for the Treatment of Systemic Scleroderma
SBC: APIE THERAPEUTICS INC Topic: NHLBIABSTRACT The goal of this STTR proposal is to develop a novel anti-fibrotic agent suitable for oral administration which could be used to safely and effectively treat Systemic Sclerosis (SSc), or Systemic Scleroderma patients. SSc is one of the most disabling and lethal immune-mediated rheumatic disorders. SSc is a rare disease, affecting 40,000-150,000 people in the United States and conferring a ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Microbial Synthesis of Therapeutic Bile Acids for Alzheimer's Disease
SBC: Metselex, Incorporated Topic: 105ABSTRACT This Phase STTR Phase II proposal aims to engineer and scale-up a synthetic metabolic pathway in a microbial host to produce UDCA and related compounds. Additionally, the UDCA produced from the engineered synthetic metabolic pathway will be used to synthesize derivatives for testing in our Alzheimer’s Disease cell and animal models. The proposed work has high intellectual merit for the ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A novel producer cell line for more efficient manufacturing of viral vector systems
SBC: CLAIRIgene Topic: 100ABSTRACT Significant advances in the specific targeting of delivery vectors and the increased therapeutic efficacy of such vectors for gene delivery have been made, stimulating major interest in the development and commercialization of therapeutic products focused on gene therapy indications. CLAIRIgene LLC focused on the development and optimization of various viral gene-to-cell transfer delivery ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Microfluidic technology platform as a continuous end-line process to inactivate pharmaceuticals
SBC: NIGHTHAWK BIOSCIENCES, INC. Topic: NCATSPROJECT SUMMARY To achieve the FDA’s required Sterility Assurance Level for use in humans, pharmaceutical products must undergo terminal sterilization or aseptic manufacturing. This can be accomplished using physical or chemical methods such as heat or formaldehyde for simple drug formulations; however, for pharmaceutical products that have more complex drug formulations or that contain biologic ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
A Therapeutic Role for Apolipoprotein-E in the Germ Theory of Alzheimer's Dementia
SBC: REGENNOVA, INC. Topic: RAbstract: A Therapeutic Role for Apolipoprotein-E in the Germ Theory of ADP. gingivalis is the keystone bacteria of periodontal disease, the 6th most common infectious disease worldwide. Half of all Americans over the age of 30 and 70% of those over age 65 suffer some degree of P. gingivalis infection associated with gum disease. In a study of 6800 patients with gum disease that were followed for ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of an Effective Strategy to Block Nab Activity for AAV Brain Transduction
SBC: NABGEN INC Topic: NCATSAdeno-associated virus (AAV) vectors have been successfully employed in patients with rare neurological diseases. Recently, two AAV based gene therapy drugs have been approved by the FDA, Luxturna been valued at $850,000 with a one-time application for blindness and Zolgensma at $2,100,000 for spinal muscle atrophy. AAV vector mediated gene therapy has shown to be a potentially huge market. Althou ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Amadorins as a Novel Oral Therapeutic for Diabetic Retinopathy
SBC: Praetego Inc Topic: NEIPROJECT SUMMARY Diabetic Retinopathy (DR) is a serious diabetic complication that is the leading cause of vision loss in working- age adults, affecting more than 7.5 million people in the USA. It causes more new cases of blindness than any other eye disease in people between the ages of 18 and 65. The anti-VEGF treatments can slow the progress of DR in many patients but are only used after signifi ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Leptin Receptor Agonist to Treat Sleep Disordered Breathing
SBC: Arrevus, Inc. Topic: NHLBIPROJECT SUMMARY/ABSTRACT Obstructive sleep apnea (OSA) and obesity hypoventilation syndrome (OHS) are the most common types of sleep disordered breathing (SDB). OSA is highly prevalent in the United States, affecting 20-40% of the adult population and more than 50% of individuals with obesity. Approximately 20% of individuals with obesity develop OHS defined as daytime hypercapnia and hypoventilat ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a treatment for durable remission of HIV using transposon engineered CAR-T and NK cells
SBC: MARPAM PHARMA LLC Topic: NIAIDProject Summary MarPam Pharma aims to develop a one-time treatment for achieving durable remission of human immunodeficiency virus (HIV), after which patients will no longer need to take antiretroviral therapy. Our treatment is an autologous HIV-specific chimeric antigen receptor (CAR) immune cell therapy that employs the CXCR5 chemokine receptor as a homing device to direct either anti-HIV T cell ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Improved Treatment of Colorectal Cancer with CF10
SBC: Deep Creek Pharma, LLC Topic: 102PROJECT SUMMARY Decades of modulating the anti-cancer activity of fluoropyrimidine drugs (FPs) thru schedule optimization, biochemical modulation, and drug combinations have provided a significant, but limited, survival advantage for treating colorectal cancer (CRC) patients with locally advanced or metastatic disease (mCRC). However, outcomes remain poor for patients with mCRC and since targeted ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health